Skip to content

A multicenter real event clinical study on evaluating the safety of betamethasone hydrochloride tablets

A multicenter real event clinical study on evaluating the safety of betamethasone hydrochloride tablets

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080128
Enrollment
Unknown
Registered
2024-01-22
Start date
2024-01-31
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Betamethasone hydrochloride tablets are used to treat dizziness , tinnitus , and hearing related to Meniere syndrome

Interventions

Standard dose group of betamethasone hydrochloride tablets:NA

Sponsors

Wenzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. According to the drug instructions , patients who are clinically applying betamethasone hydrochloride tablets ;2.Age=18 years old , regardless of gender ;3. Obtaining informed consent from the patient or guardian

Exclusion criteria

Exclusion criteria: 1. According to the contraindications , precautions , and any contraindications or other circumstances that prohibit the use of betamethasone hydrochloride tablets listed in the approved instructions for the use of betamethasone hydrochloride tablets ;2. Those with poor compliance who are unable to complete or refuse to complete follow - up ;3. Patients with mental disorders and other factors that affect compliance ;4. Individuals who are known to be allergic to the components of this medicine .

Design outcomes

Primary

MeasureTime frame
Liver function;Renal function;

Countries

China

Contacts

Public ContactYe Hua

Wenzhou People's Hospital

40707729@qq.com+86 139 6880 0035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026